| Objective To investigate the influence of bigeminy combination lipid-lowering therapy on clinical efficacy and laborato?ry parameters of acute cerebral infarction patients complicated with hypertension and dyslipidemia.Methods 130 acute cerebral in?farction patients complicated with hypertension and dyslipidemia were chosen in our hospital from January 2016 to March 2018 and randomly grouped into control group (65 patients) with statins and experiment group (65 patients) with statins + ezetimibe on the basis of systematic intervention; and the NIHSS score, mRS score, BARTHEL index score, the levels of SBP, DBP, TC, TG, HDL-C, LDL-C,TNF-α,IL-6 and vaspin before and after treatment of both groups were compared.Results The NIHSS score, mRS score, BARTHEL index score, the levels of SBP, DBP, TC, TG, HDL-C and LDL-C, TNF- α, IL-6 and vaspin of experiment group after treatment separate?ly for (6.82±1.04)points, (1.87±0.32)points, (54.78±7.27)points, (131.04±12.10)mmHg, (83.15±4.70)mmHg, (3.92±0.71)mmol/L, (2.47±0.33)mmol/L,(1.17±0.31)mmol/L,(2.84±0.54)mmol/L,(25.91±4.67)μg/L,(139.41±25.68)ng/L,(12.95±1.45)mg/L were significant better than control group for (8.46±1.50)points,(2.45±0.49)points,(46.30±5.93)points,(139.55±18.56)mmHg,(88.46±6.09)mmHg,(4.63±0.84)mmol/L,(2.83±0.40)mmol/L,(0.97±0.23)mmol/L,(3.50±0.63)mmol/L,(39.43±6.80)μg/L,(172.24±32.95)ng/L,(10.87±1.27)mg/L and be?fore treatment for (14.59±2.28)points, (3.79±0.78)points, (29.83±4.07)points, (148.74±22.70)mmHg, (94.26±7.28)mmHg, (5.25±1.17)mmol/L,(3.20±0.58)mmol/L,(0.79±0.13)mmol/L,(3.96±0.79)mmol/L,(81.93±14.03)μg/L,(262.72±46.54)ng/L,(9.23±1.04)mg/L(P<0.05).Conclusion Bigeminy combination lipid-lowering therapy in the treatment of acute cerebral infarction patients complicated with hy?pertension and dyslipidemia can efficiently promote the improvement of neurological function, higher the quality of life, control blood pressure and blood lipids, inhibit the release of inflammatory factors and be helpful to up regulate the expression of vaspin. |
